Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jones Lang LaSalle Inc (JLL) vs Sanofi SA (SNY) Price & Performance

Jones Lang LaSalle IncTrade

Price performance (Past 24H)

Key statistics

Jones Lang LaSalle Inc vs Sanofi SA — how do they compare? Jones Lang LaSalle Inc trades at $362.41 (market cap $16.72B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 6.2× Jones Lang LaSalle Inc's market cap, and Sanofi SA pays a 5.55% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.

JLLSNY
Market Cap
$16.72B$104.30B
Sector
Real EstateHealth
52-Week High
$373.24$52.34
52-Week Low
$280.16$41.33
Enterprise Value
$19.48B$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jones Lang LaSalle Inc

JLL trades at $362.81, up 1.53% today, near its 52-week high. The stock exhibits strong technical momentum with a bullish moving average crossover and is supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Revenue growth accelerated to $26.12 billion in 2025, with net income margin improving to 3.64%. Analyst sentiment is positive with a 54.55% buy rating and a consensus price target of $391.50, suggesting further upside potential from current levels.

The outlook for JLL is favorable, driven by robust earnings performance and solid cash flow generation. Key opportunities include continued growth in leasing and capital markets, while risks involve economic sensitivity and competitive pressures in real estate services. The stock's valuation at a P/E of 17.43 and P/S of 0.63 appears reasonable relative to growth prospects.

Sanofi SA

SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.

The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Jones Lang LaSalle Inc

Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.

Read more on JLL

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY